Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 252

1.

The roles of multiparametric magnetic resonance imaging, PCA3 and prostate health index-which is the best predictor of prostate cancer after a negative biopsy?

Porpiglia F, Russo F, Manfredi M, Mele F, Fiori C, Bollito E, Papotti M, Molineris I, Passera R, Regge D.

J Urol. 2014 Jul;192(1):60-6. doi: 10.1016/j.juro.2014.01.030. Epub 2014 Feb 8.

2.

Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.

Sciarra A, Panebianco V, Cattarino S, Busetto GM, De Berardinis E, Ciccariello M, Gentile V, Salciccia S.

BJU Int. 2012 Dec;110(11):1661-5. doi: 10.1111/j.1464-410X.2012.11146.x. Epub 2012 May 4.

3.

Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy.

Scattoni V, Lazzeri M, Lughezzani G, De Luca S, Passera R, Bollito E, Randone D, Abdollah F, Capitanio U, Larcher A, Lista G, Gadda GM, Bini V, Montorsi F, Guazzoni G.

J Urol. 2013 Aug;190(2):496-501. doi: 10.1016/j.juro.2013.02.3184. Epub 2013 Mar 1.

PMID:
23466239
4.

Prostate cancer gene 3 and multiparametric magnetic resonance can reduce unnecessary biopsies: decision curve analysis to evaluate predictive models.

Busetto GM, De Berardinis E, Sciarra A, Panebianco V, Giovannone R, Rosato S, D'Errigo P, Di Silverio F, Gentile V, Salciccia S.

Urology. 2013 Dec;82(6):1355-60. doi: 10.1016/j.urology.2013.06.078. Epub 2013 Sep 29.

PMID:
24080222
5.

A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.

Auprich M, Augustin H, Budäus L, Kluth L, Mannweiler S, Shariat SF, Fisch M, Graefen M, Pummer K, Chun FK.

BJU Int. 2012 Jun;109(11):1627-35. doi: 10.1111/j.1464-410X.2011.10584.x. Epub 2011 Sep 21.

6.

Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study.

Thompson JE, Moses D, Shnier R, Brenner P, Delprado W, Ponsky L, Pulbrook M, Böhm M, Haynes AM, Hayen A, Stricker PD.

J Urol. 2014 Jul;192(1):67-74. doi: 10.1016/j.juro.2014.01.014. Epub 2014 Feb 8.

PMID:
24518762
7.

PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study.

Gittelman MC, Hertzman B, Bailen J, Williams T, Koziol I, Henderson RJ, Efros M, Bidair M, Ward JF.

J Urol. 2013 Jul;190(1):64-9. doi: 10.1016/j.juro.2013.02.018. Epub 2013 Feb 14.

PMID:
23416644
8.

Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy.

Perdonà S, Bruzzese D, Ferro M, Autorino R, Marino A, Mazzarella C, Perruolo G, Longo M, Spinelli R, Di Lorenzo G, Oliva A, De Sio M, Damiano R, Altieri V, Terracciano D.

Prostate. 2013 Feb 15;73(3):227-35. doi: 10.1002/pros.22561. Epub 2012 Jul 20.

PMID:
22821756
9.

Urinary PCA3 as a predictor of prostate cancer in a cohort of 3,073 men undergoing initial prostate biopsy.

Chevli KK, Duff M, Walter P, Yu C, Capuder B, Elshafei A, Malczewski S, Kattan MW, Jones JS.

J Urol. 2014 Jun;191(6):1743-8. doi: 10.1016/j.juro.2013.12.005. Epub 2013 Dec 11.

PMID:
24333241
10.

PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial.

Aubin SM, Reid J, Sarno MJ, Blase A, Aussie J, Rittenhouse H, Rittmaster R, Andriole GL, Groskopf J.

J Urol. 2010 Nov;184(5):1947-52. doi: 10.1016/j.juro.2010.06.098. Epub 2010 Sep 17.

PMID:
20850153
11.

The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation.

Nicholson A, Mahon J, Boland A, Beale S, Dwan K, Fleeman N, Hockenhull J, Dundar Y.

Health Technol Assess. 2015 Oct;19(87):i-xxxi, 1-191. doi: 10.3310/hta19870. Review.

12.

Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml.

Ferro M, Bruzzese D, Perdonà S, Marino A, Mazzarella C, Perruolo G, D'Esposito V, Cosimato V, Buonerba C, Di Lorenzo G, Musi G, De Cobelli O, Chun FK, Terracciano D.

PLoS One. 2013 Jul 4;8(7):e67687. doi: 10.1371/journal.pone.0067687. Print 2013.

13.

Evaluation of PCA3 and multiparametric MRI's: collective benefits before deciding initial prostate biopsy for patients with PSA level between 3-10ng/mL.

Okcelik S, Soydan H, Ates F, Berber U, Saygin H, Sonmez G, Karademir K.

Int Braz J Urol. 2016 May-Jun;42(3):449-55. doi: 10.1590/S1677-5538.IBJU.2015.0155.

14.
15.

Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers.

Ferro M, Bruzzese D, Perdonà S, Mazzarella C, Marino A, Sorrentino A, Di Carlo A, Autorino R, Di Lorenzo G, Buonerba C, Altieri V, Mariano A, Macchia V, Terracciano D.

Clin Chim Acta. 2012 Aug 16;413(15-16):1274-8. doi: 10.1016/j.cca.2012.04.017. Epub 2012 Apr 20.

PMID:
22542564
16.

Usefulness of pre-biopsy multiparametric magnetic resonance imaging and clinical variables to reduce initial prostate biopsy in men with suspected clinically localized prostate cancer.

Numao N, Yoshida S, Komai Y, Ishii C, Kagawa M, Kijima T, Yokoyama M, Ishioka J, Matsuoka Y, Koga F, Saito K, Masuda H, Fujii Y, Kawakami S, Kihara K.

J Urol. 2013 Aug;190(2):502-8. doi: 10.1016/j.juro.2013.02.3197. Epub 2013 Mar 7.

PMID:
23473904
18.

[Does PCA3 score and prostatic MRI help selection of patients scheduled for initial prostatic biopsy?].

Vinet M, Vlaeminck-Guillem V, Rouvière O, Perrin P, Paparel P, Devonec M, Adam E, Briant PE, Ruffion A.

Prog Urol. 2013 Feb;23(2):121-7. doi: 10.1016/j.purol.2012.09.005. Epub 2012 Oct 18. French.

PMID:
23352305
19.

Value of PCA3 to predict biopsy outcome and its potential role in selecting patients for multiparametric MRI.

Leyten GH, Wierenga EA, Sedelaar JP, van Oort IM, Futterer JJ, Barentsz JO, Schalken JA, Mulders PF.

Int J Mol Sci. 2013 May 28;14(6):11347-55. doi: 10.3390/ijms140611347.

20.

Utility of multiparametric magnetic resonance imaging suspicion levels for detecting prostate cancer.

Rais-Bahrami S, Siddiqui MM, Turkbey B, Stamatakis L, Logan J, Hoang AN, Walton-Diaz A, Vourganti S, Truong H, Kruecker J, Merino MJ, Wood BJ, Choyke PL, Pinto PA.

J Urol. 2013 Nov;190(5):1721-1727. doi: 10.1016/j.juro.2013.05.052. Epub 2013 May 29.

PMID:
23727310

Supplemental Content

Support Center